Answers are grounded in this paper and cite their sources.
Impaired wound repair is a major complication of diabetes, yet how microbiota-derived metabolites sustain inflammation remains unclear. By integrating metabolomic and microbiome profiling of individuals with type 2 diabetes, we identify phenylethylamine as an elevated microbiota-associated metabolite. In mouse cutaneous and oral wounds, phenylethylamine promotes neutrophil extracellular trap formation and delays wound healing. Mechanistically, phenylethylamine signals through trace amine-associated receptor 1 on neutrophils, engaging β-arrestin-extracellular signal-regulated kinase-reactive oxygen species signaling. Microbiota depletion lowers circulating phenylethylamine, whereas Enterococcus faecalis recolonization increases its concentration and delays repair, supporting a microbial contribution to phenylethylamine exposure. Local delivery of a receptor antagonist in a thermosensitive hydrogel reduces neutrophil extracellular traps and improves cutaneous and oral healing in diabetic mice. These findings provide preclinical support for local TAAR1 blockade as a potential approach to improving diabetic wound repair.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: